At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 78 enrolled
Drug / intervention
Tezepelumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 1 clinical trial evaluating Tezepelumab and Placebo for Atopic Dermatitis and Healthy Volunteers. Completed, enrolled 78 participants.
Detailed Summary
This study is a single dose escalation study of tezepelumab (AMG 157) in healthy adults (Part A) and adults with moderate to severe atopic dermatitis (Part B). The purpose of the study is to evaluate the safety, tolerability, immunogenicity and pharmacokinetics of tezepelumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis, Healthy Volunteers
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedSep 2008
Primary CompletionJan 2011
TodayJul 2026
First PostedSep 22, 2008
Enrollment StartSep 18, 2008
Primary CompletionJan 5, 2011
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 17.8 years ago
Interventions
Tezepelumabdrug
Administered by subcutaneous or intravenous injection
Placebodrug
Matching placebo administered by subcutaneous or intravenous injection.